Correa S, Guerra-Torres XE, Waikar SS, et al. - Presence of higher serum magnesium in chronic kidney disease (CKD) patients was identified to be associated with lower systolic (SBP) and diastolic blood pressure (DBP), as well as with a lower risk of hypertension and CKD progression. Further exploration is needed to determine if magnesium supplementation in CKD cases could optimize blood pressure (BP) control and prevent disease progression.

• Data were collected from 3,866 participants from the CRIC Study (Chronic Renal Insufficiency Cohort), to examine the association of serum magnesium with the development of hypertension and CKD progression in patients with CKD.

• Among participants, lower SBP (−3.4 mm Hg [95% CI, −5.8 to −1.0 per 1 mEq/L]) and lower DBP (−2.9 mm Hg [95% CI, −4.3 to −1.5 per 1 mEq/L]) were observed in relation to higher magnesium.

• A lower risk of American Heart Association–defined hypertension (SBP≥130 mm Hg or DBP≥80 mm Hg) at baseline (adjusted hazard ratio, 0.65) as well as a lower risk of suboptimally controlled BP (SBP≥120 mm Hg or DBP≥80 mm Hg; adjusted odds ratio, 0.58) was observed in relation to higher magnesium.

• Time-to-event analyses revealed a nominally lower risk of incident CRIC-defined hypertension (adjusted hazard ratio, 0.77) in relation to higher baseline serum magnesium.

• Presence of higher magnesium was related to a significantly lower risk of CKD progression (adjusted hazard ratio, 0.68).